Schroder Investment Management Group
ALLO icon

Schroder Investment Management Group’s Allogene Therapeutics ALLO Stock Holding History

Schroder Investment Management Group’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-168,864
Closed -$535K – 1187
2023
Q3 		$535K Hold
168,864
– – ﹤0.01% 1086
2023
Q2 		$839K Sell
168,864
-9,043
-5% -$48.9K ﹤0.01% 1068
2023
Q1 		$879K Sell
177,907
-12,792
-7% -$82K ﹤0.01% 1070
2022
Q4 		$1.2M Buy
+190,699
New +$1.77M ﹤0.01% 1031

Other funds holding ALLO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Schroder Investment Management Group's ALLO Position: Q4 2023 in Review

Schroder Investment Management Group sold out of Allogene Therapeutics (ALLO) in Q4 2023, closing a stake of 168,864 shares — an estimated $535K sold.

Schroder Investment Management Group first reported a position in ALLO in Q4 2022 and held it in 4 quarters. The position peaked at $1.2M in Q4 2022. 170 funds tracked by Wall St. Rank hold ALLO as of Q4 2023.

  • Schroder Investment Management Group reported no remaining Allogene Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Schroder Investment Management Group sold 168,864 Allogene Therapeutics shares in Q4 2023, an estimated $535K.
  • Schroder Investment Management Group first reported a position in Allogene Therapeutics in Q4 2022 and held it in 4 quarters.
  • Schroder Investment Management Group's Allogene Therapeutics position peaked at $1.2M in Q4 2022.
  • 170 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q4 2023.

Based on Schroder Investment Management Group's 13F filing for Q4 2023, filed 14 Feb 2024.